利用尿液生物标志物评估2019冠状病毒病严重程度
该单中心回顾性研究纳入58例经实时逆转录聚合酶链反应确诊的SARS-CoV-2阳性患者,按病情分为重症组(需ICU治疗,n=12)、中度组(需氧疗,n=13)和轻度组(n=33),系列检测尿β2-微球蛋白和肝型脂肪酸结合蛋白。结果发现低水平与轻症相关,高水平与重症相关;重症患者肝型脂肪酸结合蛋白倾向于持续升高。重症 vs 中度+轻度:β2-微球蛋白截断值2457 μg/dL(特异性76.9%,敏感性90.0%,AUC 85.9%),肝型脂肪酸结合蛋白截断值22.0 μg/gCre(特异性84.6%,敏感性90%,AUC 91.8%)。作者认为评估此类尿液生物标志物可能有助于判断存在活跃细胞因子的COVID-19患者并识别可能转为危重症、需要密切观察和早期干预的患者。
要点
- 重症 vs 中度+轻度:尿β2-微球蛋白截断值2457 μg/dL,敏感性90.0%、特异性76.9%,AUC 85.9%。
- 重症 vs 中度+轻度:尿肝型脂肪酸结合蛋白截断值22.0 μg/gCre,敏感性90%、特异性84.6%,AUC 91.8%。
- 低β2-微球蛋白和肝型脂肪酸结合蛋白水平与轻症相关,高水平与重症相关。
- 重症病例中肝型脂肪酸结合蛋白倾向于持续升高。
- 尿β2-微球蛋白与血清干扰素-γ/单核细胞趋化蛋白-1呈现相似趋势。
适用人群与场景
- 经实时逆转录聚合酶链反应检测呼吸道标本SARS-CoV-2阳性的58例患者。
- 按病情分组:需ICU治疗者为重症组(n=12),需氧疗者为中度组(n=13),其余为轻度组(n=33)。
诊断标准与关键阈值
- 重症 vs 中度+轻度:尿β2-微球蛋白截断值2457 μg/dL(特异性76.9%,敏感性90.0%,AUC 85.9%)。
- 重症 vs 中度+轻度:尿肝型脂肪酸结合蛋白截断值22.0 μg/gCre(特异性84.6%,敏感性90%,AUC 91.8%)。
研究设计与关键结果
- 单中心回顾性研究,纳入58例SARS-CoV-2阳性患者,分为重症组(n=12,需ICU治疗)、中度组(n=13,需氧疗)和轻度组(n=33)。
- 系列检测尿β2-微球蛋白和肝型脂肪酸结合蛋白,同时评估血清干扰素-γ和单核细胞趋化蛋白-1。
- 低β2-微球蛋白和肝型脂肪酸结合蛋白水平与轻症相关,高水平与重症相关;重症病例中肝型脂肪酸结合蛋白倾向于持续升高。
- 重症 vs 中度+轻度:β2-微球蛋白截断值2457 μg/dL(特异性76.9%,敏感性90.0%,AUC 85.9%)。
- 重症 vs 中度+轻度:肝型脂肪酸结合蛋白截断值22.0 μg/gCre(特异性84.6%,敏感性90%,AUC 91.8%)。
- 尿β2-微球蛋白与血清干扰素-γ/单核细胞趋化蛋白-1呈现相似趋势。
证据类型、等级与局限
- 证据类型:单中心回顾性研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,评估尿β2-微球蛋白和肝型脂肪酸结合蛋白等尿液生物标志物可能有助于判断存在活跃细胞因子的COVID-19患者,并识别可能转为危重症、需要密切观察和早期干预的患者。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
SUBJECTS: Early detection of coronavirus disease 2019 in patients likely to develop severe manifestations enables appropriate interventions, including rapid ICU admission. This study was conducted to determine whether noninvasive urine biomarkers can predict the clinical severity of coronavirus disease 2019.
INTERVENTIONS: Not applicable.
MEASUREMENTS AND MAIN RESULTS: This is single-center study, national center hospital designated for infectious disease. Fifty-eight patients who tested positive for severe acute respiratory syndrome coronavirus 2 in respiratory specimens through real-time reverse transcription-polymerase chain reaction were retrospectively studied. Urinary β2-microglobulin, liver-type fatty acid-binding protein were serially measured. Serum interferon-γ and monocyte chemotactic protein-1 were also evaluated. The 58 patients were assigned into three groups. Patients requiring intensive care were assigned to the severe group (n = 12). Patients treated with oxygen were assigned to the moderate group (n = 13). Other patients were assigned to the mild group (n = 33). Urine tests revealed that low β2-microglobulin and liver-type fatty acid-binding protein levels were associated with mild disease, whereas high levels were associated with severe disease. In severe cases, liver-type fatty acid-binding protein tended to be persistently high. The resulting cutoff values were β2-microglobulin; severe versus moderate + mild: 2,457 μg/dL (specificity 76.9% and sensitivity 90.0%, area under the receiver operating characteristic curve 85.9%), liver-type fatty acid-binding protein; severe versus moderate + mild: 22.0 μg/gCre (specificity 84.6% and sensitivity 90%, area under the receiver operating characteristic curve 91.8%). Urinary β2-microglobulin and serum interferon-γ/monocyte chemotactic protein-1 showed a similar trend.
CONCLUSIONS: Evaluating urinary biomarkers such as β2-microglobulin and liver-type fatty acid-binding protein may allow determination of coronavirus disease 2019 patients with active cytokines and recognition of patients likely to become critically ill and requiring careful observation and early intervention.
参考来源
- Katagiri D, Ishikane M, Asai Y, et al. Evaluation of Coronavirus Disease 2019 Severity Using Urine Biomarkers. Crit Care Explor. 2020. PMID: 32766565. doi:10.1097/CCE.0000000000000170
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。